🇺🇸 FDA

Company profile · Sponsor

INOVIO

INOVIO PHARMACEUTICALS, INC.

INO · NYSE pharma PLYMOUTH MEETING, PA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

INOVIO (INO) is a pharma company. headquartered in PLYMOUTH MEETING, PA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker INO
Exchange NYSE
Company type pharma
Headquarters PLYMOUTH MEETING, PA, USA
SEC CIK 0001055726

Pipeline (24)

Search pipeline →

  1. INO-4800

    INOVIO

    Coronavirus Infection

    phase 3 small molecule completed

    4 trials

  2. Medpulser Electroporation with Bleomycin

    INOVIO

    Head Neck Cancer

    phase 3 other terminated

    1 trial

  3. VGX-3100

    INOVIO

    Cervical Dysplasia

    phase 3 mab completed

    2 trials

  4. CHRONVAC-C®

    INOVIO

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule active

    1 trial

  5. ChronVac-C + SOC

    INOVIO

    Chronic Hepatitis C

    phase 2 small molecule active

    1 trial

  6. GLS-5300

    INOVIO

    Healthy

    phase 2 mab completed

    2 trials

  7. HPV DNA Plasmids Therapeutic Vaccine VGX-3100

    INOVIO

    Anal Intraepithelial Neoplasia

    phase 2 mab completed

    1 trial

  8. INO-3107

    INOVIO

    Respiratory Papillomatosis

    phase 2 small molecule completed

    1 trial

  9. INO-3112

    INOVIO

    Cervical Cancer

    phase 2 mab completed

    1 trial

  10. INO-3112

    INOVIO

    Head and Neck Squamous Cell Cancer

    phase 2 mab completed

    1 trial

  11. INO-3112 vaccine

    INOVIO

    Uterine Cervical Neoplasms

    phase 2 mab terminated

    1 trial

  12. INO-4700

    INOVIO

    Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

    phase 2 small molecule completed

    1 trial

  13. INO-5401

    INOVIO

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

  14. INO-5401

    INOVIO

    Glioblastoma

    phase 2 mab active

    1 trial

  15. PENNVAX-GP

    INOVIO

    HIV-1-infection

    phase 2 mab completed

    1 trial

  16. VGX 3100

    INOVIO

    Cervical Intraepithelial Neoplasia

    phase 2 mab completed

    1 trial

  17. VGX-3100

    INOVIO

    Anal Neoplasm

    phase 2 mab completed

    1 trial

  18. VGX-3100

    INOVIO

    Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

    phase 2 mab completed

    1 trial

  19. p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine

    INOVIO

    Leukaemia (Acute)

    phase 2 mab completed

    1 trial

  20. 2mg INO-5150 and electroporation device CELLECTRA®-5P

    INOVIO

    Prostate Cancer

    phase 1 mab completed

    1 trial

  21. Electroporation-Mediated Plasmid DNA Vaccine Therapy

    INOVIO

    Chronic Hepatitis

    phase 1 mab active

    1 trial

  22. FVH1 - a DNA-based influenza vaccine

    INOVIO

    Influenza, Human

    phase 1 mab completed

    1 trial

  23. GLS-5700

    INOVIO

    Healthy

    phase 1 mab completed

    2 trials

  24. GLS-6150

    INOVIO

    HCV Infection

    phase 1 mab completed

    1 trial

Patents (8)

Search patents →

  1. US 12285473

    Cancer vaccines targeting MUC16 and uses thereof

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12280108

    Vaccines having an antigen and interleukin-21 as an adjuvant

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12251561

    Minimally invasive dermal electroporation device

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12240872

    Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12161706

    Cancer vaccines targeting BORIS and uses thereof

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12109258

    Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12064473

    Cancer vaccines targeting Survivin and uses thereof

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12054537

    Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is INOVIO?

INOVIO (INO) is a pharma company. headquartered in PLYMOUTH MEETING, PA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does INOVIO sponsor?

We track 24 ClinicalTrials.gov-linked programs for INOVIO, including INO-4800 and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does INOVIO company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.